多替阿巴拉米片治疗效果怎么样？

It is a drug for the treatment of AIDS. Dolutegravir tablets are currently the only three-in-one compound drug containing dolutegravir (DTG). It has the characteristics of good tolerance, high resistance barrier, and few drug interactions. One tablet per day can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and significantly improving their quality of life.

Dolutegra abalamib tablets have been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment for newly diagnosed AIDS patients. Dr. Wim Swyzen, MD, head of medical affairs and vice president of GSK China/Hong Kong, said, "Through effective HIV drug treatment, the life spans of HIV patients and healthy people are getting closer and closer. Drug compliance and convenience of medication play an increasingly important role in further improving the quality of life of patients. Currently, there is no drug that can be taken once a day or one tablet at a time on the Chinese market. The approval of Dolutegra Abalamid Tablets fills this gap and meets the urgent need for convenient medication use by doctors and patients."

It can be seen that Dolutegra is a new drug used to treat AIDS and brings new hope to AIDS patients. AIDS is an infectious disease that can be transmitted through sexual contact, blood, and mother-to-child transmission. Currently, there is still a lack of effective drugs to cure HIV infection worldwide. It can only reduce the viral load to the maximum and lasting extent and improve the patient's quality of life. HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B5701 allele, he should not take products containing abacavir.

Precautions: Spreading HIV. Although viral suppression with antiretroviral therapy has been shown to significantly reduce the risk of sexual transmission, residual risks cannot be excluded. Precautions should be taken to prevent transmission in accordance with national guidance.

Hypersensitivity reactions. Both abacavir and dolutegravir carry the risk of triggering a hypersensitivity reaction (HSR) and share some common characteristics, such as fever and/or rash and other symptoms indicating involvement of multiple organs. It is clinically impossible to determine whether abacavir or dolutegravir is responsible for a hypersensitivity reaction that occurs with Trimeq. Hypersensitivity reactions have been observed to occur more commonly with abacavir, some of which can be life-threatening and, in rare cases, fatal if not managed appropriately. Patients who test positive for the HLA-B5701 allele are at higher risk of developing abacavir hypersensitivity reactions. However, abacavir hypersensitivity reactions are reported less frequently in patients who do not carry this allele.

Therefore, the following measures should be followed: HLA-B5701 status must be confirmed before starting treatment. Patients with a positive HLA-B5701 status, or patients with a negative HLA-B5701 status who had a suspected abacavir hypersensitivity reaction when previously receiving an abacavir-containing treatment regimen, should not be treated with Trimax. If a hypersensitivity reaction is suspected, Suimika should be discontinued without delay, even if the HLA-B5701 allele is not present. If a hypersensitivity reaction occurs and treatment with Trimax is not discontinued immediately, a life-threatening reaction may result. Clinical status, including hepatic aminotransferases and bilirubin, should be monitored. After discontinuing Trimax due to suspected hypersensitivity reaction, Trimax or any other medicine containing abacavir or dolutegravir should never be restarted. After a suspected hypersensitivity reaction to abacavir, symptoms may return within hours if abacavir-containing medicines are restarted. Relapses are generally more severe than the initial episode and may include life-threatening hypotension and death. To avoid re-dosing abacavir and dolutegravir, patients with suspected hypersensitivity reactions should be instructed to discard the remainder.